Evommune (NYSE:EVMN) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "buy" rating.
Evommune (NYSE:EVMN) was given a new $40.00 price target on by analysts at Raymond James Financial, Inc..
Evommune (NYSE:EVMN) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
Evommune (NYSE:EVMN) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Evommune (NYSE:EVMN) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.